300636.SHE Jiangxi Synergy Pharmaceutical Co Ltd
- Market cap
- CNY 2.72B
- P/E
- 92.6x
- P/B
- 1.14x
- ROE
- 2.1%
- Dividend yield
- 1.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300636.SHE undervalued?
Graham number300636.SHE trades 116.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangxi Synergy Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jiangxi Synergy Pharmaceutical Co Ltd yet.
Jiangxi Synergy Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-diabetes, anti-thrombotic, urology, non-alcoholic steatohepatitis, idiopathic pa…
Full company profileJiangxi Synergy Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangxi Synergy Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 250M | 297M | 267M | 413M | 435M | 592M | 720M | 722M | 759M | 829M | 811M |
| Gross Profit | 96.8M | 109M | 76.8M | 122M | 150M | 171M | 226M | 220M | 220M | 251M | 226M |
| Operating Income | 58.2M | 72.8M | 26.3M | 51.7M | 78.2M | 88.3M | 106M | 112M | 111M | 127M | 83.6M |
| EBITDA | 90.1M | 95.9M | 50.2M | 98.7M | 140M | 146M | 181M | 192M | 248M | 219M | 53.7M |
| Net Income | 58.0M | 65.5M | 24.5M | 48.3M | 70.1M | 81.1M | 101M | 106M | 107M | 73.1M | 51.3M |
| EPS | 0.25 | 0.22 | 0.08 | 0.16 | 0.23 | 0.24 | 0.29 | 0.28 | 0.25 | 0.17 | 0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 419M | 722M | 804M | 1.02B | 1.47B | 1.91B | 2.26B | 3.22B | 3.32B | 3.32B | 2.93B |
| Total Liabilities | 114M | 85.2M | 145M | 309M | 651M | 1.02B | 939M | 995M | 1.01B | 956M | 541M |
| Shareholders' Equity | 305M | 637M | 658M | 706M | 817M | 888M | 1.32B | 2.23B | 2.31B | 2.37B | 2.39B |
| Cash & Short-term Investments | 58.2M | 23.9M | 39.9M | 38.3M | 280M | 161M | 142M | 513M | 196M | 253M | 139M |
| Total Debt | 54.8M | 20.0M | 20.0M | 208M | 575M | 811M | 614M | 769M | 700M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 60.4M | 34.1M | 74.9M | -28.3M | 80.1M | 131M | 196M | 164M | 285M | 202M | - |
| Capital Expenditure | 28.9M | 115M | 242M | 184M | 230M | 425M | 311M | 215M | 136M | 291M | 217M |
| Free Cash Flow | 31.6M | -81.1M | -167M | -213M | -150M | -293M | -115M | -50.9M | 149M | -89.2M | -413K |
| Ratios | |||||||||||
| ROE | 19.0% | 10.3% | 3.7% | 6.8% | 8.6% | 9.1% | 7.6% | 4.8% | 4.6% | 3.1% | 2.1% |
| ROA | 13.8% | 9.1% | 3.1% | 4.8% | 4.8% | 4.3% | 4.5% | 3.3% | 3.2% | 2.2% | 1.8% |
| Net Profit Margin | 23.2% | 22.1% | 9.2% | 11.7% | 16.1% | 13.7% | 14.0% | 14.7% | 14.0% | 8.8% | 6.3% |
| Debt to Equity | 0.18x | 0.03x | 0.03x | 0.29x | 0.70x | 0.91x | 0.47x | 0.35x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangxi Synergy Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.06%
- Forward dividend
- 0.04 CNY
- Payout ratio
- 39.4%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 28.8M | 0.07 | 39.4% |
| 2024 | CNY 29.1M | 0.07 | 27.3% |
| 2023 | CNY 26.9M | 0.07 | 25.4% |
| 2022 | CNY 32.1M | 0.09 | 31.9% |
| 2021 | CNY 10.9M | 0.03 | 13.5% |
| 2020 | CNY 10.9M | 0.04 | 15.6% |
| 2019 | CNY 3.34M | 0.01 | 6.9% |
| 2018 | CNY 8.94M | 0.03 | 36.5% |
| 2017 | CNY 426K | 0.00 | 0.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jul 5, 2022.
Who owns Jiangxi Synergy Pharmaceutical Co Ltd
- Insiders 34.59%
- Institutions 4.75%
- Public & others 60.67%
- Shares outstanding 420M
- Free float 286M
Jiangxi Synergy Pharmaceutical Co Ltd company profile
- Company name
- Jiangxi Synergy Pharmaceutical Co Ltd
- Ticker
- 300636.SHE
- ISIN
- CNE100002P83
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,623
- Fiscal year end
- December
- Address
- Jiangxi Fengxin High-tech Industrial Park, Yichun, China, 330700
- Phone
- 86 79 5460 5771
- Website
- jxsynergy.com
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-diabetes, anti-thrombotic, urology, non-alcoholic steatohepatitis, idiopathic parkinsonism, hypolipidemic agents, migraine therapy, prostate cancer, endometriosis, anemia, atopic dermatitis, nervous system, digestive system, antipyretic analgesics and non-steroidal anti-inflammatory, anticoagulant, hypoglycemic drug, and antidepressant indications. It also provides intermediate products, including rivaroxaban, apixaban, empagliflozin, canagliflozin, ipragliflozin, mirabegron, vibegron, agomelatine, febuxostat, vildagliptin, vonoprazan fumarate, dabigatran etexilate mesylate, azilsartan base and medoxomil potassium, candesartan cilexetil, rimegepant, resmetirom, and opicapone. In addition, the company offers contract manufacturing organization (CMO) services, including production capacity, good manufacturing practice (GMP), regulatory support, research and development for process optimization and scale-up production, and environmental, health, and safety (EHS) management systems. It exports its products to Europe, the United States, Japan, and South Korea. Jiangxi Synergy Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Yichun, the People's Republic of China.
Jiangxi Synergy Pharmaceutical Co Ltd management
9- Mr. Zhengwei PangChairman & GM · born 1962
- Mr. Zhongcheng LiangVice Chairman & Deputy GM · born 1965
- Mr. Jinqiao HuFinancial Director · born 1983
- Mr. Yuansen JiangDeputy GM & Director · born 1963
- Mr. Guojun HuangDeputy GM & Director · born 1964
- Mr. Zhicheng ZhouDeputy GM & Secretary of the Board · born 1972
- Mr. Liyong ZhouDeputy General Manager · born 1987
- Mr. Weiping HuangDeputy General Manager · born 1982
- Bo WangAccounting Supervisor